Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1474-1482

  Smith, Leia M ^a   Nesterova, Albina ^a   Alley, Stephen C ^a   Torgov, Michael Y ^a,b   Carter, Paul J ^a  

^a SEATTLE GENETICS INC   (United States)

^b CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; CITRULLINE; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY L49 MONOMETHYLAURISTATIN F CONJUGATE; PROTEIN P97; PROTEINASE; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG CONJUGATION; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; ENDOSOME; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYSOSOME; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; MELANOMA; MICE; NEOPLASM PROTEINS; OLIGOPEPTIDES; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33746095034     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0026     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Woodbury RG, Brown JP, Yeh MY, Hellström I, Hellström KE. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A 1980;77:2183-7.
3. Brown JP, Woodbury RG, Hart CE, Hellström I, Hellström KE. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A 1981;78:539-43.
4. Estin CD, Stevenson U, Kahn M, Hellström I, Hellström KE. Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97. J Natl Cancer Inst 1989;81:445-8.
5. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004;11: 659-87.
6. Woodbury RG, Brown JP, Loop SM, Hellström KE, Hellström I. Analysis of normal neoplastic human tissues for the tumor-associated protein p97. Int J Cancer 1981;27:145-9.
7. Alemany R, Vila MR, Franci C, Egea G, Real FX, Thomson TM. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J Cell Sci 1993; 104:1155-62.
8. Sciot R, de Vos R, van Eyken P, van der Steen K, Moerman P, Desmet VJ. In situ localization of melanotransferrin (melanoma-associated antigen P97) in human liver. A light- and electronmicroscopic immunohistochemical study. Liver 1989;9:110-9.
9. Richardson DR. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur J Biochem 2000;267:1290-8.
10. Real FX, Mattes MJ, Houghton AN, Oettgen HF, Lloyd KO, Old LJ. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med 1984;160:1219-33.
11. Brown JP, Hewick RM, Hellström I, Hellström KE, Doolittle RF, Dreyer WJ. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature 1982;296:171-3.
12. Rose TM, Plowman GD, Teplow DB, Dreyer WJ, Hellström KE, Brown JP. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A 1986;83:1261-5.
13. Food MR, Rothenberger S, Gabathuler R, Haidl ID, Reid G, Jefferies WA. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. J Biol Chem 1994;269: 3034-40.
14. Michaud-Levesque J, Demeule M, Beliveau R. Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion. Exp Cell Res 2005;308:479-90.
15. Kim DK, Seo MY, Lim SW, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology 2001;25:84-90.
16. Richardson DR, Morgan EH. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim Biophys Acta 2004;1690: 124-33.
17. Siemers NO, Kerr DE, Yarnold S, et al. Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug Chem 1997;8:510-9.
18. Hellström I, Brown JP, Hellström KE. Melanoma-associated antigen p97 continues to be expressed after prolonged exposure of cells to specific antibody. Int J Cancer 1983;31:553-5.
19. Klussman K, Mixan BJ, Cerveny CG, Meyer DL, Senter PD, Wahl AF. Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. Bioconjug Chem 2004; 15:765-73.
20. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
21. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17: 114-24.
22. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66:2328-37.
23. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci 2003;116:4707-14.
24. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002;54:431-67.
25. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-42.
26. Law CL, Klussman K, Wahl AF, Senter P, Doronìna SO, Toki BE, inventors; Seattle Genetics Inc., assignee. Treatment of immunological disorders using anti-CD30 antibodies. U.S. patent application US 20050123536. 2005 Jun 9.
27. McMillian MK, Li L, Parker JB, et al. An improved resazurin-based cytotoxicity assay for hepatic cells. Cell Biol Toxicol 2002;18:157-73.
28. Casellas P, Brown JP, Gros O, et al. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int J Cancer 1982;30:437-43.
29. Garrigues HJ, Tilgen W, Hellström I, Franke W, Hellström KE. Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer 1982;29:511-5.
30. Hellström I, Garrigues HJ, Cabasco L, Mosely GH, Brown JP, Hellström KE. Studies of a high molecular weight human melanoma-associated antigen. J Immunol 1983;130:1467-72.
31. Rothenberger S, Food MR, Gabathuler R, et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res 1996;712:117-21.
32. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
33. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004;10:7842-51.
34. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268-82.
35. Jefferies WA, Gabathuler R, Rothenberger S, Food M, Kennard ML. Pumping iron in the '90s. Trends Cell Biol 1996;6:223-8.
36. Danielsen EM, van Deurs B. A transferrin-like GPI-linked iron-binding protein in detergent-insoluble noncaveolar microdomains at the apical surface of fetal intestinal epithelial cells. J Cell Biol 1995;131:939-50.
37. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001;3:473-83.
38. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005;11:843-52.